News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
byStephen Padilla
Reducing the dose of trastuzumab deruxtecan (T-DXd) does not have any significant effect on real-world (rw) progression-free survival (PFS) or treatment-related toxicities among patients with metastatic breast cancer (MBC), as shown in a Singapore study.
Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients
29 Sep 2025
byStephen Padilla
Smoking, obesity, treatment duration, and pre-existing cardiac diseases may contribute to the development of cardiotoxicity among patients with cancer who are undergoing 5-fluorouracil (5-FU) chemotherapy, suggests a recent study.







